Ethics and ego dissolution: the case of psilocybin

William R Smith; Dominic Sisti

doi:10.1136/medethics-2020-106070

Article menu

Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts

PDF

Original research

Ethics and ego dissolution: the case of psilocybin

Free

Share this article

Click the icon of the social media platform on which you would like to share this article.

Share This Article:

Email this article to a friend

We will not keep your email address; we ask for it so your friend knows the email isn't spam.

Your email: *

Your name: *

Send to: *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Ethics and ego dissolution: the case of psilocybin

Message subject: (Your Name) has forwarded a page to you from Journal of Medical Ethics

Message body: (Your Name) thought you would like to see this page from the Journal of Medical Ethics web site.

Your personal message:

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Read the full text or download the PDF:

Log in using your username and password

For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?

Forgot your user name or password?

Other content recommended for you

Psychedelic crossings: American mental health and LSD in the 1970s
Lucas Richert et al., Medical Humanities, 2019
Research abuses against people of colour and other vulnerable groups in early psychedelic research
Dana Strauss et al., Journal of Medical Ethics, 2021
Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)
Mathias Ebbesen Jensen et al., BMJ Open, 2022
Prescribing meaning: hedonistic perspectives on the therapeutic use of psychedelic-assisted meaning enhancement
Riccardo Miceli McMillan, Journal of Medical Ethics, 2020
Chronic pain and psychedelics: a review and proposed mechanism of action
Joel P Castellanos et al., Regional Anesthesia & Pain Medicine, 2020
PSYCHEDELIC DRUGS, MAGICAL THINKING AND PSYCHOSIS
Robin Carhart-Harris, Journal of Neurology, Neurosurgery & Psychiatry, 2013
Pharmacotherapy of anxiety disorders in the 21st century: A call for novel approaches
Eric Bui et al., General Psychiatry, 2019
Psychedelic injustice: should bioethics tune in to the voices of psychedelic-using communities?
Riccardo Miceli McMillan, Medical Humanities, 2022
Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting
Elena Argento et al., BMJ Open, 2017
Open-label trial of anterior limb of internal capsule–nucleus accumbens deep brain stimulation for obsessive-compulsive disorder: insights gained
Daniel Huys et al., Journal of Neurology, Neurosurgery & Psychiatry, 2019

Log in using your username and password

Main menu

Log in using your username and password

You are here

Share this article

Email this article to a friend

Request permissions

Read the full text or download the PDF:

Log in using your username and password

Other content recommended for you